A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Palmoplantar Pustulosis
Public ClinicalTrials.gov record NCT03633396. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Randomized, Placebo-controlled, Double-blind, Multiple Dose Study to Evaluate the Efficacy and Safety of ANB019 in Subjects With Palmoplantar Pustulosis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
A study to evaluate the efficacy and safety, and pharmacokinetic (PK) profile of multiple doses of imsidolimab (ANB019) in adults with palmoplantar pustulosis (PPP)
Study identification
- NCT ID
- NCT03633396
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 59 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 20, 2019 (Actual)
- Primary completion
- Apr 23, 2021 (Actual)
- Completion
- Apr 23, 2021 (Actual)
- Last update posted
- Sep 15, 2025
2019 – 2021
United States locations
- U.S. sites
- 19
- U.S. states
- 13
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Investigational Site | Birmingham | Alabama | 35233 | — |
| Investigational Site | Phoenix | Arizona | 85032 | — |
| Investigational Site | Encino | California | 91436 | — |
| Investigational Site | Santa Monica | California | 90405 | — |
| Investigational Site | Fort Lauderdale | Florida | 33316 | — |
| Investigational Site | Miami | Florida | 33155 | — |
| Investigational Site | Pembroke Pines | Florida | 33028 | — |
| Investigational Site | Tampa | Florida | 33607 | — |
| Investigational Site | Indianapolis | Indiana | 46250 | — |
| Investigational Site | Plainfield | Indiana | 46168 | — |
| Investigational Site | Overland Park | Kansas | 66215 | — |
| Investigational Site | Ann Arbor | Michigan | 48109 | — |
| Investigational Site | St Louis | Missouri | 63110 | — |
| Investigational Site | St Louis | Missouri | 63117 | — |
| Investigational Site | Wilmington | North Carolina | 28405 | — |
| Investigational Site | Columbus | Ohio | 43230 | — |
| Investigational Site | Norman | Oklahoma | 73071 | — |
| Investigational Site | Portland | Oregon | 97239 | — |
| Investigational Site | Dallas | Texas | 75230 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 20 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03633396, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 15, 2025 · Synced Oct 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03633396 live on ClinicalTrials.gov.